Margaret C. Fang, MD, MPH

Use of dual antiplatelet therapy was modest for patients with existing cardiovascular disease for whom subgroup analysis from a landmark clinical trial suggested benefit in preventing cardiovascular events, and low for patients with multiple risk factors without established cardiovascular disease, for whom increased cardiovascular events were suggested.